Chemoresistance Cell signalling Ceritinib Trametinib Prognosis Anti-PD-1 Merkel cell carcinoma Androgen insensitivity Adverse events Acute generalized exanthematous pustulosis Bariatric surgery Mesenchymal stromal cells CARMN Sonic Hedgehog BRAF V600-mutation Diagnosis Molecular targeted therapies Cemiplimab Immune checkpoint inhibitor Adjuvant Anti-PD-1 antibody Cemiplimab Cutaneous squamous cell carcinoma Follow-up Locally advanced Metastatic Radiotherapy Surgical excision Treatment Brain Metastases Cancer ADN tumoral circulant Colorectal carcinoma Adjuvant therapy Lung adenocarcinoma Antineoplastic agents Children Nivolumab Chemotherapy Dabrafenib Polyomavirus Advanced melanoma ALK rearrangement Staging Abdominal pain Invasive cutaneous squamous cell carcinoma Langerhans cell histiocytosis Gastric bypass Cancer Stem Cells Adjuvant Metastatic cSCC Anti-PD1 blockade Anti-PD1 Histiocytosis Plasma ACTH Anti-PD-1 antibody Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian Systemic therapy Anti-Tumor pharmacology Immunohistochemistry TNM classification BRAF V600E Colon cancer Anti-CTLA-4 Safety Immunotherapy C797S Colorectal cancer Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation Melanoma EGFR COVID-19 Wnt Radiofrequency ablation Cancer bronchique non à petites cellules Non-small cell lung cancer Osimertinib Radiotherapy Biomarkers Crizotinib Cancers of the Colon AZD9291 BRAFV600E BRAFV600-mutant melanoma Adjuvant FOLFOX Survival BRAFV600E mutation Targeted therapy Prognostic Resistance Biomarker Circulating tumor DNA Body mass index Abscopal effect Antibody-drug conjugate AML Bone marrow niche BRAF Allelic imbalance Biliopancreatic diversion 2-chlorodeoxyadenosine Advanced Prevention Immunomodulation ALK Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy Beta-catenin Circulating cell-free DNA